Archive | March, 2022

Who’s Pitching at Digital RESI March?

10 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Innovator’s Pitch Challenge (IPC) returns in two weeks as part of Digital RESI, March 22-24. The IPC is a highly anticipated and popular feature of the virtual Digital RESI format. Representing therapeutics, medical devices, diagnostics, and digital health, finalists use the opportunity to showcase their technology to registered RESI attendees, which include over 300 active early-stage life science investors. Each company will have a dedicated landing page that includes their pitch video, slide deck, executive summary, and other marketing collateral. These companies will also be engaging in a live Q&A session with investors who have relevant expertise, which will help them prepare for future investor meetings. These sessions often lead to engaging follow-on discussions and valuable, long-term connections.

Check out each finalist below and learn more about the Digital RESI JPM winners!

  1. First Place: Amplified Sciences – Making a Difference One Impression at a Time
  2. Second Place: OncoXome – Family Matters in Fundraising
  3. Third Place: Prolifagen – Ascending the Steep Slope of Preclinical Fundraising

Digital RESI March 2022 IPC Finalists

resi-march-2022

Workshops at Digital RESI March

10 Mar

By Alexander Vassallo, Manager of Business Development West Coast (US), LSN

Digital RESI March provides valuable opportunities to partner with hundreds of active investors seeking early-stage assets in life science and healthcare, but equally valuable are the resources provided by key strategic partners providing the services necessary for business growth. Life Science Nation (LSN) is pleased to feature experienced industry professionals attending the March 22-24 Digital RESI partnering conference and hosting exciting workshops designed specifically to address the pain points of early-stage scientist-entrepreneurs raising their Seed to Series B funding rounds. Check out our workshops below and register to start booking meetings today!

Tuesday, March 22, 12 PM EDT

Keeping Your Life Science Startup Out of the ‘Valley of Death’
Instructor: Nishta Rao, MBA, Managing Director, Life Sciences, First Republic Bank
Moderated by First Republic Bank’s Nishta Rao, hear from CEOs and founders on their pain points and strategies on navigating their company out of the valley of death.

Tuesday, March 22, 1 PM EDT

Employee Risk Mitigation in Startups
Instructors:
Samuel Bilsky, Sales Consultant, TriNet
Anna Evans, Senior Consultant – Technology, TriNet
In the digital age, it’s important for entrepreneurs to prioritize their company’s most valuable asset: people. This session will detail how full-service HR can save precious time for entrepreneurs to focus on what matters while knowing their team is taken care of. In a sea of possibilities, understand your HR options, learn about PEO services, and how they can help scale your business with big-company benefits and infrastructure. There’s no one-size-fits all, so get tips on finding the right HR solution for your organization.

Wednesday, March 23, 12 PM EDT

Branding & Messaging: Seed to Series B
Instructors:
Claire (Chae-Kyeong) Jeong, VP of Investor Research, Asia Business Development, Life Science Nation
Candice He, VP of Business Development, Global Investment Strategist, Life Science Nation
To win capital, you must stand out from the crowd. The first way to do that is to have top-notch marketing collateral. This bootcamp discusses how to provide potential investors with high-quality, professional materials—materials that engage them, communicate your message clearly and concisely, and present the information they want to see in a way that helps them to decide quickly and easily if you are a potential fit for their needs.

Thursday, March 24, 12 PM EDT

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?
Instructors:
Mark Mihanovic, Partner, McDermott Will & Emery
Aroma Sharma, Partner, McDermott Will & Emery
This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

resi-march-2022

Fill Your Dance Card in March

10 Mar

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

As Digital RESI, March 22-24 ramps up, so has interest from the RESI investor community. With over 300 investors already registered for the event, including large pharma/medtech, traditional VCs, family offices/private wealth, and angel groups, this virtual event is shaping up to be buzzing with activity and digital meetings.

What sets RESI apart from many partnering events is the Life Science Nation (LSN) dedicated Investor Research Team responsible for ensuring that each investor’s partnering profiles are comprehensive and up-to-date. This conference is an excellent opportunity for entrepreneurs and founders to expand their network in the industry and connect with investors and strategic partners that are a fit for their company. With less than two weeks left, the partnering activities are at their peak and there is no better time to reach out to investors and book meetings. Register now to connect with these investors at Digital RESI March:

CI-03102022

resi-march-2022

Hot Investor Mandate: Healthcare-Focused VC with USA and Asia Offices Invests in Cutting Edge Life Sciences and Digital Health Solutions Across the Globe

10 Mar

An early-stage healthcare venture fund with teams in USA and Asia  looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.

The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.

The firm is focused on two main investment themes: (1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages; (2) Digital Health / Bio IT

Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.

The firm is looking for experienced management teams with strong scientific expertise and management skills.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Early-Stage Venture Fund Invests in Novel Therapeutics Companies in Oncology and Autoimmune Diseases, Invests Primarily in Western Europe

10 Mar

An active early stage venture fund based in Western Europe has a team composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. The firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. The firm is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Evergreen Fund Invests in Seed to Later-Stage Companies in Medical Devices, Diagnostics, Digital Health, and AI-Related Technologies

10 Mar

An evergreen fund focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Initial investment sizes fall within a wide range. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments.  The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. AME is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. AME is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: East Coast-Based Investment Fund Seeks Opportunities in Aging Related Technologies and Digital Health in North America and Israel

10 Mar

The firm is an East Coast-based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a leading university leveraging the network of schools and 70,000 + alumni network to help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including SilverTech™ (Seniors and Tech), PropTech, Fintech, Cybersecurity HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.

Within HealthTech, the firm invests in SilverTech™ and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.

The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value,  they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →